Use of Low-frequency Magnetic Fields in the Hybrid Treatment of COVID-19 Patients
COVID-19, COVID-19 Respiratory Infection, COVID-19 Pneumonia
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring COVID-19, magnetostimulation, interleukin, treatment
Eligibility Criteria
Inclusion Criteria:
- patients hospitalized due to PCR-confirmed SARS - Cov - 2 infection
Exclusion Criteria:
- patients with absolute contraindications to magnetic field application
- patients with limited verbal - logical contact were excluded from the study
Sites / Locations
- Department of Rehabilitation and Physical Medicine, Medical University of LodzRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Patients with COVID - 19, who we were treated with magnetic stimulation.
Patients with COVID - 19, who we were treated without magnetic stimulation.
The study group included patients hospitalized due to PCR-confirmed SARS-Cov-2 infection, who were treated with magnetic stimulation in addition to a standard therapy. Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization.
The control group included patients receiving a comprehensive treatment without magnetic stimulation. The patients were in a moderately severe condition.